To establish the incidence and correlation of increased left atrial volume index (LAVI) in patients with first-ever ischemic stroke.
S
troke is a major cause of mortality, morbidity, and disability [1] [2] [3] in both developed and developing countries 1,2 and contributes to the age-associated epidemic of cardiovascular disease. A robust physiologic biomarker for risk can lead to the development of effective primary and secondary prevention strategies. During the past few years, left atrial volume (LAV), which correlates with the chronicity of increased left ventricular filling pressure, 4, 5 has been shown to be associated with the risk of cardiovascular disease, including morbidity and mortality of coronary artery disease, [5] [6] [7] atrial fibrillation, 8, 9 stroke, 10 systemic thromboembolism, 11, 12 and congestive heart failure (CHF). 13, 14 In the current study, indexed LAV at the time of firstever ischemic stroke was examined and assessed in terms of its association with other conventional stroke risk factors, 8, 15 stroke subtype, 16, 17 and survival. Further, we compared incident stroke cases to a population-based sample of controls for which LAV and other clinical risk factors were also available.
PARTICIPANTS AND METHODS
With approval from the Mayo Clinic Institutional Review Board, 963 patients were identified from the medical records-linkage system of the Rochester Epidemiology Project as having first-ever ischemic stroke between January 1, 1985, and December 31, 1994 . 16, 18, 19 Clinical data were collected prospectively and followed over a maximum of 12.5 years (mean ± SD follow-up, 4.2±3.4 years). In this cohort of 963 patients, 531 did not undergo transthoracic echocardiography (TTE) within 60 days of diagnosis of ischemic stroke; these patients make up the no-TTE group and were excluded from the primary analysis of the study but were used to assess potential selection bias associated with having TTE at the time of stroke. The TTE group consisted of 432 patients who had at least 1 TTE within 60 days of the stroke. Of these, 4 patients refused consent and 4 patients' original TTE videotapes were unavailable, leaving 424 TTE patients with first-ever ischemic stroke and a potentially usable comprehensive 2-dimensional TTE. The assessment of selection bias was based on comparing the clinical characteristics of these 2 groups, specifically stroke subtype and cardiovascular risk factors at the time of the first ischemic stroke. However, the primary comparison group was a community-based study group drawn from the Stroke Prevention: Assessment of For personal use. Mass reproduce only with permission from Mayo Clinic Proceedings. For personal use. Mass reproduce only with permission from Mayo Clinic Proceedings.
Risk in the Community (SPARC) study, which is described in detail below.
CLINICAL DATA
The stroke database contained clinical data obtained through comprehensive review of the medical records. History of hypertension, CHF, myocardial infarction, coronary artery disease, atrial fibrillation, and diabetes mellitus were documented before or at the time of stroke and were extracted for both the TTE and no-TTE groups. Definitions of these clinical variables have been published previously. 16, 18 ECHOCARDIOGRAPHIC DATA Of the 424 patients in the TTE group, 5 with unusual causes of stroke (eg, dissection and vasculitis) were excluded from further analysis, and 113 other patients were subsequently excluded because of poor echocardiographic images unsuitable for LAV measurement. This group of 113 patients was compared with those who had usable images in terms of clinical characteristics, again to check for possible selection bias. In the remaining 306 patients, LAV was measured offline using the biplane area-length method, 10, 13, 20 without knowledge of the clinical data, and indexed to body surface area (mL/m 2 ). The LAV index (LAVI) was categorized as normal (<28 mL/m 2 ) or increased (≥28 mL/m 2 ) on the basis of LAVI quantitative guidelines of the American Society of Echocardiography. 20 
STROKE SUBTYPES
Stroke subtypes were classified on the basis of the National Institute of Neurological Disorders and Stroke [16] [17] [18] and Trial of Org 10172 in Acute Stroke Treatment 17 criteria as unknown cause (105 patients; 34%), cardioembolic (89 patients; 29%), lacuna (63 patients; 21%), large-vessel atherosclerosis with stenosis of at least 50% (47 patients; 15%), and unknown subtype (2 patients) ( Table 1) .
CONTROL GROUP
Data relating to the distribution of LAV in the community were obtained from the SPARC study, a population-based study conducted between August 1, 1998, and June 30, 1999 . Participants in this study were randomly sampled from sex and age strata ranging from 50 to 100 years. All 490 participants had TTE. Although the community-based study was not initially designed to measure LAV, 416 participants (85%) had TTE images that were suitable for LAV measurement using the biplane area-length method. We removed 19 controls who had a history of stroke, leaving 397 participants in the control group.
We also obtained clinical data, such as history of CHF, hypertension, diabetes mellitus, and stroke or transient ischemic attack (TIA) from the SPARC study. Collection of these data allowed us to calculate, both for the stroke cases and the SPARC controls, the CHADS 2 score. 21 (CHADS stands for the components of the score: CHF, hypertension, age, diabetes mellitus, and stroke or TIA.) This stroke risk index assigns 1 point each for the presence of CHF, history of hypertension, age older than 75 years, and diabetes mellitus and 2 points for history of stroke or TIA. We then assessed the predictive accuracy of CHADS 2 separately and together with LAVI in correctly distinguishing patients from controls.
STATISTICAL ANALYSES
Data are presented as mean ± SD for continuous variables and frequency percentages for categorical variables. For skewed variables, medians and first and third quartiles are reported. Differences in baseline characteristics between stroke patients with normal and increased LAVI and between the TTE and no-TTE groups were assessed using the 2-sample t test or Wilcoxon rank sum test for continuous variables and the χ 2 test for categorical variables. A cardiovascular risk factor score was calculated by counting the number of risk factors (history of hypertension, CHF, atrial fibrillation, coronary artery disease, and diabetes mellitus) each stroke patient had.
The association of LAVI with stroke was assessed in several ways. First, the rate of increased LAVI was compared between the control group and the patients with stroke within each age decade using χ 2 tests. Population attributable risk (PAR) associated with increased LAVI was estimated with the Levin formula 22 by using the odds ratios from the age-stratified tables of case status vs LAVI category. Second, linear regression models were used to assess the association of LAVI with stroke vs control status after adjusting for age and sex. Finally, to study the association of LAVI with stroke risk while controlling for age and sex, conditional logistic regression was performed, with conditioning strata formed from the combination of sex with each 3-year age category (centered on ages divisible by 3). The separate and combined effects of CHADS 2 and log (LAVI) on stroke risk were also calculated using this same conditional logistic regression approach.
Kaplan-Meier methods were used to estimate rates of death after stroke in the patients, both overall and within the subsets with normal and increased LAVI. Univariable and multivariable Cox proportional hazards regressions were used to test and estimate predictive associations with survival. The 1-sample log-rank test was used to compare observed survival estimates with expected survival on the basis of age-and sex-specific mortality rates from the Minnesota white population.
In all cases, statistical significance was defined as 2-tailed P<.05. Analysis was performed using JMP, version 5.1.2, and SAS, version 9.1.3 (SAS Institute, Cary, NC). Table 1 shows patients' characteristics overall and by LAVI category. Of the 306 patients with first-ever stroke, 180 (59%) were female, and the mean ± SD age was 75±12 years. Mean ± SD LAVI was 42±21 mL/m 2 (median, 37 mL/m 2 , with first and third quartile levels of 28 and 48 mL/m 2 ). A total of 230 patients (75%) had increased LAVI (49±21 mL/m 2 ). In the 76 patients with normal LAVI, mean ± SD LAVI was 23±3 mL/m 2 . Patients with increased LAVI were older (76±11 vs 71±13 years; P=.003), had more cardiovascular risk factors (1.8±0.07 vs 1.3±0.89; P<.001), and were more likely to have more than 1 risk factor (55% vs 36%; P<.004) than patients with normal LAVI. The Figure shows the percentages of patients with normal and increased LAVI who had each cardiovascular risk factor. Patients with the cardioembolic stroke subtype had the highest prevalence of increased LAVI (84/89 patients, 94%), which was significantly higher than that in patients with the lacunar (50/63 patients, 79%; P=.005), large-vessel atherosclerosis (31/47 patients, 66%; P<.001), and unknown (64/105 patients, 61%; P<.001) subtypes.
RESULTS

PATIENTS WITH STROKE
Significant differences were observed between patients with stroke with TTE and those with no TTE in age (74±6 years vs 78±6 years; P<.001) and in the prevalence of CHF (14% vs 22%; P=.01) but not in the prevalence of other risk factors, ie, hypertension, myocardial infarction, mitral valve disease, atrial fibrillation, coronary artery disease, and diabetes mellitus. The results suggest that, although some differences existed between the patients who did and did not receive TTE, we were able to adjust for those variables (age and CHF) in the analysis. Table 2 shows the baseline demographic and clinical characteristics of patients and controls using a modified version of the CHADS 2 scheme. Patients and controls were significantly different with respect to age, each of the clinical risk factors, and the CHADS 2 score. Among the 397 control patients, 195 (49%) were female, the mean ± SD age was 68±11 years, and 207 (52%) had increased LAVI. The mean ± SD LAVI was 32±24 mL/m 2 (median, 29 mL/m 2 , with first-and third-quartile levels of 24 and 37 mL/m 2 ), which is 25% less than the mean in patients with stroke (P<.001).
CONTROLS
INCREASED LAVI IN PATIENTS AND CONTROLS
The percentages of patients and controls with increased LAVI by decade of age are shown in Table 3 . The difference between patients and controls in the rate of increased LAVI varied with age, being greater between patients and controls younger than 80 years but less or nonexistent between patients and controls aged 80 years or older. PAR calculations using the Levin formula 22 performed on the age strata in Table 3 yielded a PAR of 89.1 of 306 patients (29%) due to increased LAVI. Because the SPARC study did not assess participants younger than 50 years, this PAR is likely an underestimate. When linear regression was used to relate LAVI to age, sex, and patient-control status, both age and patient-control status were independently predictive of LAVI (all, P<.001), whereas sex was not an independent predictor.
Conditional logistic regression predicting case status (with a separate stratum for each sex and 3-year age group combination) was used to estimate the association of LAVI and CHADS 2 , separately and in combination, with the risk of stroke (Table 4) . When considered separately, both LAVI and CHADS 2 had significant associations with patient status. The odds ratio for stroke associated with a 1.5-fold increase in LAVI (eg, from 28 to 42 mL/m 2 ) was 1.66 (log likelihood ratio χ 2 =27.9; P<.001), whereas the odds ratio associated with each point increase in CHADS 2 was 1.78 (χ 2 =40.0; P<.001). When considered together in the same model, the adjusted odds ratios for LAVI and CHADS 2 were 1.52 per 1.5-fold increase in LAVI (P<.001) and 1.82 per unit increase in CHADS 2 (P<.001), respectively, with a model χ 2 of 63.6. When interactions between age and these 2 variables were considered, significant interactions were observed for each variable when separately 2 , each year of age was associated with a decrease of 0.0529 (P<.001) in the effect of each additional point of CHADS 2 on log (odds) of stroke (model χ 2 =73.9). The odds ratio associated with 1 CHADS 2 point was estimated to be 6.71 at age 50 years, but 0.81 at age 90 years and 1.37 at age 80 years.
When interactions for both variables with age were considered simultaneously (Table 4) , only the age interaction for CHADS 2 remained significant, implying that the odds ratio per unit increase of CHADS 2 was 5.8 at age 50 years, but only 1.35 at age 80 years; the odds ratio for 1.5-fold increase of LAVI was 2.04 at age 50 years and 1.48 at age 80 years. The model χ 2 for this latter model was 91.1.
FOLLOW-UP OF PATIENTS WITH STROKE
Survival in patients with stroke was compared with expected survival in Minnesota's white population and was further modeled as a function of age, sex, LAVI, and clinical risk factors. Of the 306 patients with stroke, 181 patients died (mean ± SD LAVI, 52±23 mL/m 2 ) after stroke during a median follow-up of 5.2 years. The Kaplan-Meier survival rate in these patients was 55% at 5 years (95% confidence interval [CI], 50%-61%) and 33% at 10 years (95% CI, 27%-40%) and was significantly reduced compared with expected survival on the basis of age-and sexspecific mortality in Minnesota's white population during the study period (1-sample log-rank test, P<.001). Fiveyear Kaplan-Meier estimates of survival (all-cause mortality) in patients with normal and increased LAVI were 61%±6% and 53%±3%, respectively (hazard ratio [HR], 1.39; 95% CI, 0.98-2.01; log rank P=.07).
PREDICTORS OF MORTALITY
In Cox regression models for time to death, independent predictors of mortality were age (HR, 
DISCUSSION
The principal findings in this study were that increased LAVI (LAVI ≥28 mL/m 2 ) (1) was present in most patients (75%) with first-ever ischemic stroke; (2) was more prevalent in older patients and in those who had a higher number of common cardiovascular risk factors; (3) affected most patients in all ischemic stroke subtypes but was highly prevalent (94%) in the cardioembolic subtype (Table 1) ; (4) was more prevalent in patients with stroke than in age-and sex-matched controls, and log (LAVI) was independently associated with stroke risk after con- trolling for age, sex, and the CHADS 2 score; and (5) was predictive of survival in patients with stroke, independent of age, sex, and risk factor score. The relative risk of stroke at the age of 50 years associated with a change in LAVI from 28 to 42 mL/m 2 was estimated to be 3.7, whereas the relative risk at the age of 93 years associated with the same LAVI difference was 1.0. The population risk attributable to increased LAVI (LAVI ≥28 mL/m 2 ) was estimated to be 29%. Moreover, we found LAVI, treated as a continuous variable, to be a significant predictor of mortality after adjusting for age, sex, and risk factor score.
Normal LAVI is 22±6 mL/m 2 . 23, 24 LAVI is relatively unaffected by normal vacillations in disease intensity and cardiac loading conditions 25 and therefore tends to reflect the average physiologic burden. Increased LAVI is an established cardiovascular biomarker reflecting the burden of chronic elevation of ventricular filling pressure, 26 which is predictive of general cardiovascular morbidity and mortality independent of age, sex, and other conventional risk factors. [5] [6] [7] [27] [28] [29] [30] The current study suggests that LAVI is strongly related to the magnitude of stroke risk. In contrast, acute-phase reactant plasma biomarkers such as C-reactive protein 31 and B-type natriuretic peptide 32 can be too "short term," whereas duration and intensity of common clinical risk factors can vary too much to provide strong risk stratification of individual patients. 33, 34 Bos et al 31 demonstrated that although C-reactive protein was a risk factor for stroke, it could not stratify high and low risk of stroke well, nor could it predict stroke after adjusting for age, sex, and Framingham risk score.
Common age-associated cardiovascular diseases such as CHF, atrial fibrillation, and hypertension often cluster and might, like stroke, be mere consequences of a common underlying physiologic perturbation. In older people, onset of CHF and atrial fibrillation, which are strongly associated with the occurrence of stroke, is almost uniformly preceded by increased LAVI. 8, 10, 20, 35 A 3-decade study of patients with lone atrial fibrillation showed that stroke was unrelated to the duration or type of atrial fibrillation but was strongly related to increased LAVI. 36 In the current study, 44 patients (14%) had CHF and 68 patients (22%) had atrial fibrillation at the time of ischemic stroke presentation, and 42 (95%) and 62 (91%) of these patients, respectively, had enlarged left atria. In contrast, hypertension was present in 246 patients (80%) of this cohort, and only 130 (72%) of these patients had enlarged atria. Thus, although hypertension is common in age-associated disease and closely related to stroke, 37 it is not a necessary component of atrial enlargement. 38 The physiologic burden reflected in an increased LAVI appears to precede most first-ever ischemic strokes, regardless of stroke subtype. However, the absence of increased LAVI in 25% of patients is equally interesting and suggests a unique subset of patients with alternative risks such as paradoxical embolism (patent foramen ovale), 39 clotting disorders, and the like. This group needs further study.
COMPARISON WITH CONTROLS
Age-and sex-adjusted comparison with a population-based control sample showed that LAVI was strongly associated with first cardioembolic events in this cohort, independent of age and sex. Inclusion of an age-LAVI interaction term in the conditional logistic regression model suggested that the magnitude of the relative stroke risk associated with LAVI was greater among younger patients. According to this model, there was no association between stroke risk and LAVI at the age of 93 years. At the age of 50 years, by contrast, a change in LAVI from 28 mL/m 2 to 42 mL/m 2 (50% increase) was associated with a stroke risk ratio of 3.7 (a 270% increase). On the basis of the age-stratified rates of increased LAVI in both patients and controls, the PAR was estimated to be 29%, representing the proportion of stroke risk in the whole cohort that could be preventable if increased LAVI were prevented. Joint analysis of the CHADS 2 score and log (LAVI) in the conditional logistic model shows that CHADS 2 and log (LAVI) made separate independent, ie, complementary, contributions to prediction of stroke. CHADS 2 is a clinical profile, whereas LAVI is a physiologic and morphological feature of general cardiovascular and cerebrovascular risk and burden. Further, when the effects of these variables were allowed to vary, the effect of CHADS 2 was significantly attenuated with age, whereas that of log (LAVI) did not change significantly with age. Fang et al 40 noted the limited predictive value of 5 risk schemes, including the CHADS 2 index and the Framingham score. Our results suggest that LAVI provides incremental value to CHADS 2 for prediction of thromboembolism.
It was previously reported that survival after ischemic stroke was significantly lower than estimates of expected survival on the basis of Minnesota's white population.
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Patients in this study were a subset of the cohort in that report, selected for having TTE within 60 days of their stroke; they also had reduced mortality compared with expected mortality (P<.001). Moreover, LAVI was independently predictive of death, after adjusting for age and risk factor score (HR, 1.08 per 10 mL/m 2 ; P=.03). Thus, even in this high-risk group of patients with stroke (mean age >75 years), LAVI, considered as a continuous variable, was found to be a potentially useful biomarker of differential risk. Primary stroke prevention and risk reduction on the basis of a morphophysiologic biomarker is an appealing concept that merits further study. 
STUDY STRENGTHS AND LIMITATIONS
The population-based nature of this particular study cohort avoids the bias inherent in studies of patients evaluated at tertiary care centers or in community-based studies of patients referred for hospitalization or evaluation by neurologists specializing in stroke. By including only patients with first-ever ischemic stroke, this study also avoids the potential bias associated with studying patients with recurrent stroke and better reflects risk in the community.
Our study has a few limitations. First, the population studied was predominantly white, and future studies are needed to verify the extent to which the findings can be generalized to other racial and ethnic groups. Second, it was impossible to assess the contribution of medical therapy to a change in LAV in this study. Third, during the era of this study, only 50% of patients with stroke had TTE, and our analysis was necessarily limited to this subset. However, when patients who did not have TTE were compared with those who did have TTE, the only differences noted were that patients in the no-TTE group were older and had more CHF. These differences can be explained by inclusion of elderly nursing home patients who had more cardiovascular risk factors, eg, CHF, but did not receive TTE because of their prestroke morbidity. Petty et al 18 demonstrated, on the basis of the Rankin Disability Scale (which was used to measure functional status of patients), that patients with cardioembolic stroke had poorer prestroke functional status with more severe neurologic deficit at the time of stroke compared with other subtypes. In any case, we were able to control for both of these factors in the analysis. Thus, it is unlikely that the association of LAVI with stroke incidence or with survival is caused by selection bias.
CONCLUSION LAVI, as a morphophysiologic biomarker, reflects a patient's risk burden associated with aging and disease. LAVI holds promise as a useful means of assessing risk independent of conventional stroke risk factors and might be useful in developing diagnostic and preventive therapeutic strategies.
